Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34009003

about

Role of the tumor microenvironment in mature B-cell lymphoid malignancies The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date New strategies in chronic lymphocytic leukemia: shifting treatment paradigms Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma Targeted therapies in CLL: mechanisms of resistance and strategies for management Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib The tumor microenvironment shapes hallmarks of mature B-cell malignancies.The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment The biology behind PI3K inhibition in chronic lymphocytic leukaemia Secondary mutations as mediators of resistance to targeted therapy in leukemia An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity.The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.

P2860

Q26748775-DEE07282-756F-4571-9065-4882E029B0F3 Q26751006-314485B3-7868-475D-A600-602606CD6025 Q26765624-A7AC2CAE-ACD6-441F-9F93-0FD4BAA3D160 Q26766292-09F43AF7-DC00-4A51-94D4-0A2879DBADAC Q26775506-7B1918B8-7128-467B-BC8A-00988F7501F0 Q26779129-13A2B397-ABF5-4B19-843D-2228A1D9452E Q26781895-3FE5DA41-199B-4E40-AF77-39D1314F6EBB Q26782270-939D2D89-14E4-4BCB-97BD-3F73AD4F950F Q26782633-9A99EEFA-E587-4B2B-BF85-4FD0B9C762D9 Q26796455-AC038D26-3CAE-4619-A7CB-0DA22F4AA08D Q26798062-9629BCAF-3E62-4C3B-A0E2-E65AE8BFF414 Q26828496-C0A05E7B-676D-4ED8-8897-3E015BB0CAB7 Q26851417-576818D2-0FF1-4537-82DE-A8D194B43A18 Q26865645-BFF0ED45-F931-407F-A21C-76050A4F3368 Q27002528-93848523-9E48-4722-9F11-E250E384A794 Q27025812-3AECD08B-0ABC-4CEF-ABAA-0DA5147609B5 Q27687567-2EDD82DF-C767-4C20-BFB7-86DFF64C39BB Q28075504-6C1A1C0F-3DBA-431C-9056-1A49851CDD47 Q28075683-FBA60604-73FA-467A-A90A-04BADBFC2BD7 Q28077136-2C25F65F-181D-4F0D-969E-A41148AD87D3 Q28082086-D8E1BBAD-0A14-4FEF-96AB-382D7D2B473B Q28083266-848C0520-2DEB-43CF-9746-829A24E20AE8 Q28087213-B92BB6C7-84D1-4AA8-9B45-1126018329A9 Q28257366-5587F6CB-E6D2-426A-94B5-E1080EF78F11 Q28539394-059F2E08-BF79-4393-A148-F870506ACE0C Q28548425-69E829B3-5EB1-41DE-85A6-79931EE39B0B Q30365752-7711807F-5F81-42DA-A5EB-AD0772A48B4A Q30838969-AC488324-8D0E-4222-ABAE-CB50C345BE9F Q31070331-3A4CD4BE-EEF8-4B63-B7F2-472DCF6A4D4A Q33413834-F4930996-D893-4B19-9871-253CF45A28A9 Q33419789-A534532B-2180-475D-B5DA-16F46B159B6B Q33420278-C747F51D-B8D4-49B3-BEA0-B24D078813A4 Q33424543-93E61890-40A5-4DC8-9A91-26BC8B68BACB Q33433009-8EF48056-38D8-4F99-BAB0-EBE567610316 Q33438825-7373C1C4-4D3E-422C-996B-7737F8DC611A Q33440942-75449279-1F2C-48D9-A5E8-814DFDCD2FD8 Q33578997-99D4966A-3FE8-4451-B845-E227764A6569 Q33649977-4CC73269-AEDB-4376-8D13-6295F1B8C403 Q33785941-5635E25A-4518-4056-B50A-F52DDBA5AC57 Q33871417-4D4B21C9-3BB4-4D36-8B00-F6588DCBD214

P2860

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34009003

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@ast

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@en

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@nl

type

label

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@ast

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@en

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@nl

prefLabel

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@ast

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@en

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@nl

P1433

Q34009003-6F4BAFFB-184B-4B2D-A721-70627FC8D090

P1476

Q34009003-D6F30E6D-4026-49CD-813E-479CBF958D4D

P2093

Q34009003-067E1A89-9FCA-49B5-B624-9BDA4680B27D

Q34009003-09ED4F25-46D7-40C5-ACD6-54D6D337B4D6

Q34009003-25CEB1C1-C96E-46DB-A9A2-C99A5668A76F

Q34009003-2AEB5AFB-84AC-4273-AFD7-6EDB857CE079

Q34009003-3141F425-68B3-4BC8-9F42-E6606774B57F

Q34009003-4B22E4D4-2EFF-4C7B-B1FE-58A1FD77A0A2

Q34009003-809D0543-5D7F-4844-80C0-F989BCE6E0CC

Q34009003-8226D6D1-DF65-4E8B-961B-D8B342331033

Q34009003-91593C0C-AF32-46F7-886C-EDC50A393D81

Q34009003-916EF445-C129-4970-99C8-CE9B35AD669D

P2860

Q34009003-0B93FFBE-C053-4165-8DB4-C4FA420C6D5B

Q34009003-12CEEC97-0F38-4F46-8322-7EE0F84B708D

Q34009003-3E0B02E8-3454-4C09-995D-52A1D3BCA9AF

Q34009003-415FF04A-AA5F-47C7-856A-86630C5172CD

Q34009003-6A947B51-9F8F-4410-A8D1-E29F254771DB

Q34009003-7608EF60-0FEE-4EC6-9AD3-4F199F2C6198

Q34009003-7B58E394-AD57-4A19-A7A8-67854EF50412

Q34009003-7BB2D98A-76B0-4DC3-A432-4DAF02F10761

Q34009003-7F33EE1D-7117-43A9-8944-4BB7F955AE59

Q34009003-857C61A7-8268-41BD-A13C-7C87AD118AD2

P304

Q34009003-DB700B87-B03E-4E71-9A0D-E179A82998D7

P31

Q34009003-57998B24-E99B-4E54-99C7-355361E4D5AB

P356

Q34009003-934E6A11-410D-4FBE-BCA3-9CBF92F2C8EC

P407

Q34009003-2FB9F3E0-5E45-4F8C-BF23-5DCCE51BB25B

P433

Q34009003-2A91FBDA-72C7-4EAA-B86C-C57D4BA36E65

P478

Q34009003-D83316CE-1AC4-4C2A-B49D-F96817923348

P50

Q34009003-273AEB51-5027-441B-8B21-342EAA4C63D8

P577

Q34009003-B46AC8AB-E256-434A-9C51-2CFC04B63647

P698

Q34009003-794F3B35-2D68-474B-A8F8-F7A940F14363

P921

Q34009003-70922A00-981A-4D8C-8C08-6FCAA2232C61

Q34009003-8D1F4F7F-6682-4665-9AF7-C79014E59ECB

Q34009003-C6130FB3-9B44-4330-AF47-A4266197EFDE

P932

Q34009003-D1DBD0A4-E62F-4643-BB11-BD28EEEB0999

P356

BLOOD-2013-11-535047

P1433

P1476

Idelalisib, an inhibitor of ph ...... chronic lymphocytic leukemia.

@en

P2093

Albert S Yu

http://www.w3.org/2001/XMLSchema#string

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Brian J Lannutti

http://www.w3.org/2001/XMLSchema#string

Celeste Bello

http://www.w3.org/2001/XMLSchema#string

Daniel Li

http://www.w3.org/2001/XMLSchema#string

Dave M Johnson

http://www.w3.org/2001/XMLSchema#string

Don M Benson

http://www.w3.org/2001/XMLSchema#string

Heather K Webb

http://www.w3.org/2001/XMLSchema#string

Ian W Flinn

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The PI3K pathway as drug target in human cancer

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

PI3K in lymphocyte development, differentiation and activation

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

P304

3390-3397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-11-535047

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24615777

http://www.w3.org/2001/XMLSchema#string

P921

P932

4123414

http://www.w3.org/2001/XMLSchema#string